AI and Batteries: Last Hope for Hong Kong's Forgotten Stocks

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Hong Kong's forgotten small-caps are scrambling for relevance as traditional revenue streams dry up. Greenleaf Pharma (2186.HK) pivoted hard to CNS drugs, betting on its newly approved ERZOFRI® and September's AI-powered drug delivery partnership with METIS TECHBIO to escape the 'second BeiGene' narrative. Meanwhile, Wasion Holdings (3393.HK) landed a $170M Middle East smart grid contract and cleared U.S. ANSI certification—rare wins for a stock drowning in sector-wide skepticism.

Contrast this with Tigerdom (2399.HK), where declining apparel revenue now dominates 79% of a shrinking business, or Yihuo International (8659.HK) struggling with 42% year-on-year plastic container sales drops. Yet even industrial strugglers see glimmers: CRCC (1186.HK) quietly launched Guangzhou Zhichu Energy Storage, while Guoxia Tech (2655.HK) drew 'buy' ratings despite 15% recent pullbacks. The real story? These stocks aren't waiting for market sentiment—they're rewriting their playbooks in real time.

Source: Global Report The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.